Cover ImageSALE
市場調查報告書

皮膚鱗狀細胞癌(cSCC) - 市場洞察,流行病學,市場預測 ∼2027年

Cutaneous Squamous Cell Carcinoma (CsCC) - Market Insights, Epidemiology and Market Forecast-2027

出版商 DelveInsight Business Research LLP 商品編碼 524523
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
皮膚鱗狀細胞癌(cSCC) - 市場洞察,流行病學,市場預測 ∼2027年 Cutaneous Squamous Cell Carcinoma (CsCC) - Market Insights, Epidemiology and Market Forecast-2027
出版日期: 2018年12月01日 內容資訊: 英文 100 Pages
簡介

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的皮膚鱗狀細胞癌(cSCC)市場相關調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,主要7個國家的市場趨勢,流行病學的預測,未滿足需求,各治療藥物的市場規模變化的預測,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 報告概要

第2章 皮膚鱗狀細胞癌(cSCC)市場概要

  • 主要7個國家的市場規模(成果值)
  • 主要7個國家的市場規模(預測值)

第3章 疾病背景和概要:皮膚鱗狀細胞癌(cSCC)

  • 簡介
  • 原因
  • 病理生理學
  • 症狀
  • 風險因素
  • 診斷

第4章 流行病學和患者人口

  • 主要7個國家的罹患數(實數、預測數)
  • 主要7個國家的罹患數:各年齡層(實數、預測數)
  • 主要7個國家的罹患數:性別(實數、預測數)
  • 主要7個國家的罹患數:各病期(實數、預測數)
  • 主要7個國家的診斷數、可治療的病例數(實數、預測數)

第5章 皮膚鱗狀細胞癌(cSCC):各國流行病學

  • 美國
    • 罹患數(實數、預測數)
    • 罹患數:各年齡層(實數、預測數)
    • 罹患數:性別(實數、預測數)
    • 罹患數:各病期(實數、預測數)
    • 診斷數、可治療的病例數(實數、預測數)
  • 歐盟5國
    • 德國
      • 罹患數(實數、預測數)
      • 罹患數:各年齡層(實數、預測數)
      • 罹患數:性別(實數、預測數)
      • 罹患數:各病期(實數、預測數)
      • 診斷數、可治療的病例數(實數、預測數)
    • 法國
      • 罹患數(實數、預測數)
      • 罹患數:各年齡層(實數、預測數)
      • 罹患數:性別(實數、預測數)
      • 罹患數:各病期(實數、預測數)
      • 診斷數、可治療的病例數(實數、預測數)
    • 義大利
      • 罹患數(實數、預測數)
      • 罹患數:各年齡層(實數、預測數)
      • 罹患數:性別(實數、預測數)
      • 罹患數:各病期(實數、預測數)
      • 診斷數、可治療的病例數(實數、預測數)
    • 西班牙
      • 罹患數(實數、預測數)
      • 罹患數:各年齡層(實數、預測數)
      • 罹患數:性別(實數、預測數)
      • 罹患數:各病期(實數、預測數)
      • 診斷數、可治療的病例數(實數、預測數)
    • 英國
      • 罹患數(實數、預測數)
      • 罹患數:各年齡層(實數、預測數)
      • 罹患數:性別(實數、預測數)
      • 罹患數:各病期(實數、預測數)
      • 診斷數、可治療的病例數(實數、預測數)
  • 日本
    • 罹患數(實數、預測數)
    • 罹患數:各年齡層(實數、預測數)
    • 罹患數:性別(實數、預測數)
    • 罹患數:各病期(實數、預測數)
    • 診斷數、可治療的病例數(實數、預測數)

第6章 現行的治療方法

  • 治療流程
  • 治療指南

第7章 已上市治療藥

  • Cemiplimab:Regeneron Pharmaceuticals
  • 作用機制
  • 法規的里程碑
  • 優點與缺點
  • 安全性和有效性
  • 產品簡介

第8章 參照報告

第9章 新藥

  • Key Cross Competition
    • Talimogene laherparepvec:Amgen
    • 法規的里程碑
    • 臨床開發
    • 產品簡介
    • 臨床實驗平台
    • Pembrolizumab:Merck Sharp&Dohme

第10章 參照報告

第11章 皮膚鱗狀細胞癌(cSCC)的市場規模

  • 主要的觀察
  • 主要7個國家的市場分析

第12章 市場分析:各國主要7個國家

  • 美國
    • 市場規模
    • 市場規模:各治療藥物
  • 德國
  • 法國
  • 英國
  • 西班牙
  • 義大利
  • 日本

第13章 市場成長要素

第14章 市場障礙

第15章 調查方法

  • 利用之資訊來源

第16章 DelveInsight的服務內容

第17章 免責聲明

第18章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0088

DelveInsight's Cutaneous Squamous Cell Carcinoma (cSCC) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Cutaneous Squamous Cell Carcinoma (cSCC) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Cutaneous Squamous Cell Carcinoma (cSCC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Cutaneous Squamous Cell Carcinoma (cSCC) - Disease Understanding and Treatment Algorithm

Cutaneous squamous cell carcinoma (cSCC), is defined as a malignant proliferation of cutaneous epithelium, which indicates 20% to 50% of skin cancers .cSCC is associated with more mutations than other common malignancies-5 times the mutation rates in lung cancer and >4 times the mutation rates in melanoma as per the Que SKT et. al. 2018.

Unlike almost all basal-cell carcinomas, cutaneous squamous cell carcinomas are associated with a substantial risk of metastasis. The prognosis is favorable and only 2-5% of SCC metastasize.

Exposure to cancer-promoting stressors and the response of the body to those exposures (host response) promote the development of cSCC. Well-known risk factors include the following: UVR exposure, Immunosuppression, Exposure to ionizing radiation or chemical carcinogens, Human papillomavirus (HPV) infection

The DelveInsight Cutaneous Squamous Cell Carcinoma (cSCC) market report gives the thorough understanding of the Cutaneous Squamous Cell Carcinoma (cSCC) by including details such as disease definition, symptoms, classification, causes, genetics and inheritance, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Cutaneous Squamous Cell Carcinoma (cSCC) in the US, Europe, and Japan.

Cutaneous Squamous Cell Carcinoma (cSCC) Epidemiology

The Cutaneous Squamous Cell Carcinoma (cSCC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC), Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC), Gender Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC), and Diagnosed and treatable Cases of Cutaneous Squamous Cell Carcinoma (cSCC)] scenario of Cutaneous Squamous Cell Carcinoma (cSCC), in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

As per Talib Najjar et. Al. Cutaneous Squamous Cell Carcinoma (cSCC) is one of the most common cancers overall in the United States. An estimated 3.5 million cases of nonmelanoma skin cancers were diagnosed in the United States in 2006; of those, approximately 80% were basal cell carcinoma (BCC) and 20% were cSCC.

According to Syril Keena T et. Al., the age-standardized incidence of cSCC ranges from 9 to 96 per 100,000 male inhabitants and 5 to 68 per 100,000 female inhabitants (2002-2007 estimates).

As per Burton KA et. Al. cSCC is diagnosed at a rate of 15-35 per 100,000 people and is expected to increase 2-4 % per year. With respect to metastatic cSCC, this disease is more common in men; people over the age of 75 years; and inhabitants of the south and mid-west USA.

DelveInsight estimates that the incident population of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM will significantly change during the study period [2016-2027].

Cutaneous Squamous Cell Carcinoma (cSCC) Drug Chapters

This segment of the Cutaneous Squamous Cell Carcinoma (cSCC) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Most Cutaneous Squamous Cell Carcinomas (cSCC) are removed via surgery or radiation therapy and, a few selective cases that are not eligibile for surgery or radiation, are treated with topical medication i.e., off-label chemotherapeutic agents like 5-Fluorouracil, EGFR inhibitors, and Antimicrotubular agents, etc.

At Present, the only FDA approved therapy for the treatment of Cutaneous Squamous Cell Carcinomas (cSCC) is Cemiplimab (Regeneron Pharmaceuticals). So, the current therapeutic market of cSCC is occupied by Regeneron's product and the above-mentioned off-label therapies.

Key players such as Vidac Pharma, Amgen, Merck & Co., and many others are involved in developing therapies for Cutaneous Squamous Cell Carcinoma. Expected launch of emerging therapies such as Talimogene laherparepvec (Amgen), VDA-1102 (Vidac Pharma) and Pembrolizumab (Merck Sharp & Dohme) and other compelling treatments, are expected to change the treatment landscape of Cutaneous Squamous Cell Carcinoma in upcoming years.

Cutaneous Squamous Cell Carcinoma (cSCC) Market Outlook

The Cutaneous Squamous Cell Carcinoma (cSCC) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM is expected to change from 2016-2027.

Cutaneous Squamous Cell Carcinoma (cSCC) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cutaneous Squamous Cell Carcinoma (cSCC) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Cutaneous Squamous Cell Carcinoma (cSCC) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Cutaneous Squamous Cell Carcinoma (cSCC) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Cutaneous Squamous Cell Carcinoma (cSCC) market
  • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous Squamous Cell Carcinoma (cSCC) market
  • To understand the future market competition in the Cutaneous Squamous Cell Carcinoma (cSCC) market.

Table of Contents

1. Report Introduction

2. Cutaneous Squamous Cell Carcinoma (cSCC) Market Overview at a Glance

  • 2.1. 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in 2017
  • 2.2. 7 Major Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) in 2027

3. Disease Background and Overview: Cutaneous Squamous Cell Carcinoma (cSCC)

  • 3.1. Introduction
  • 3.2. Causes
  • 3.3. Pathophysiology
  • 3.4. Symptoms
  • 3.5. Risk Factor
  • 3.6. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. 7MM Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 4.2. 7MM Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 4.3. 7MM Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 4.4. 7MM Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 4.5. 7MM Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)

5. Cutaneous Squamous Cell Carcinoma: Country- Wise Epidemiology

  • 5.1. United States
  • 5.2. Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 5.3. Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 5.4. Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 5.5. Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 5.6. Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 5.7. EU-5
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Germany
      • 5.7.2.1. Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.2.2. Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.2.3. Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.2.4. Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.2.5. Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
    • 5.7.3. France
      • 5.7.3.1. Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.3.2. Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.3.3. Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.3.4. Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.3.5. Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
    • 5.7.4. Italy
      • 5.7.4.1. Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.4.2. Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.4.3. Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.4.4. Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.4.5. Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
    • 5.7.5. Spain
      • 5.7.5.1. Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.5.2. Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.5.3. Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.5.4. Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.5.5. Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
    • 5.7.6. United Kingdom
      • 5.7.6.1. Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.6.2. Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.6.3. Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.6.4. Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
      • 5.7.6.5. Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
  • 5.8. Japan
    • 5.8.1. Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
    • 5.8.2. Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
    • 5.8.3. Gender Specific Incident Cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
    • 5.8.4. Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)
    • 5.8.5. Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) (2016-2027)

6. Treatments & Medical Practices

  • 6.1. Treatment Algorithm
  • 6.2. Treatment Guidelines

7. Marketed drug

    • 7.1.1. Cemiplimab: Regeneron Pharmaceuticals
    • 7.1.2. Mechanism of Action
    • 7.1.3. Regulatory Milestones
    • 7.1.4. Advantages & Disadvantages
    • 7.1.5. Safety and Efficacy
    • 7.1.6. Product Profile

8. To be continued in the report…

9. Emerging Therapies

  • 9.1. Key Cross Competition
    • 9.1.1. Talimogene laherparepvec: Amgen
    • 9.1.2. Regulatory Milestones
    • 9.1.3. Clinical Development
    • 9.1.4. Product Profile
    • 9.1.5. Clinical Pipeline Activity
      • 9.1.5.1. Ongoing Trials Information
      • 9.1.5.2. Clinical Trial by Phase
    • 9.1.6. Pembrolizumab: Merck Sharp & Dohme
      • 9.1.6.1. Regulatory Milestones
      • 9.1.6.2. Clinical Development
      • 9.1.6.3. Product Profile
      • 9.1.6.4. Clinical Pipeline Activity
      • 9.1.6.5. Ongoing Trials Information
      • 9.1.6.6. Clinical Trial by Phase

10. To be continued in report…

11. Cutaneous Squamous Cell Carcinoma Market Size

  • 11.1. Key Findings
  • 11.2. Total 7MM Cutaneous Squamous Cell Carcinoma (cSCC) Market Analysis
    • 11.2.1. Overview of Total Cutaneous Squamous Cell Carcinoma (cSCC) Market
      • 11.2.1.1. Market size of Cutaneous Squamous Cell Carcinoma (cSCC) Market by 7MM (2016-2027)

12. 7MM: Country-Wise Market Analysis

  • 12.1. United States Market Size
    • 12.1.1. Total Market Size of Cutaneous Squamous Cell Carcinoma (cSCC)
    • 12.1.2. Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) by Therapies
  • 12.2. Germany Market Size
    • 12.2.1. Total Market Size of Cutaneous Squamous Cell Carcinoma (cSCC)
    • 12.2.2. Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) by Therapies
  • 12.3. France Market Size
    • 12.3.1. Total Market Size of Cutaneous Squamous Cell Carcinoma (cSCC)
    • 12.3.2. Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) by Therapies
  • 12.4. United Kingdom Market Size
    • 12.4.1. Total Market Size of Cutaneous Squamous Cell Carcinoma (cSCC)
    • 12.4.2. Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) by Therapies
  • 12.5. Spain Market Size
    • 12.5.1. Total Market Size of Cutaneous Squamous Cell Carcinoma (cSCC)
    • 12.5.2. Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) by Therapies
  • 12.6. Italy Market Size
    • 12.6.1. Total Market Size of Cutaneous Squamous Cell Carcinoma (cSCC)
    • 12.6.2. Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) by Therapies
  • 12.7. Japan Market Size
    • 12.7.1. Total Market Size of Cutaneous Squamous Cell Carcinoma (cSCC)
    • 12.7.2. Market Size of Cutaneous Squamous Cell Carcinoma (cSCC) by Therapies

13. Market Drivers

14. Market Barriers

15. Report Methodology

  • 15.1. Sources Used

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight

List of Tables

  • Table 1 Incident Cases of Cutaneous Squamous Cell Carcinoma in 7MM (2016-2027)
  • Table 2 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM (2016-2027)
  • Table 3 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM (2016-2027)
  • Table 4 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM (2016-2027)
  • Table 5 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM (2016-2027)
  • Table 6 Incident Cases of Cutaneous Squamous Cell Carcinoma in the US (2016-2027)
  • Table 7 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the US (2016-2027)
  • Table 8 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the US (2016-2027)
  • Table 9 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the US (2016-2027)
  • Table 10 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the US (2016-2027)
  • Table 11 Incident Cases of Cutaneous Squamous Cell Carcinoma in the Germany (2016-2027)
  • Table 12 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Germany (2016-2027)
  • Table 13 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Germany (2016-2027)
  • Table 14 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Germany (2016-2027)
  • Table 15 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Germany (2016-2027)
  • Table 16 Incident Cases of Cutaneous Squamous Cell Carcinoma in the Italy (2016-2027)
  • Table 17 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Italy (2016-2027)
  • Table 18 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Italy (2016-2027)
  • Table 19 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Italy (2016-2027)
  • Table 20 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Italy (2016-2027)
  • Table 21 Incident Cases of Cutaneous Squamous Cell Carcinoma in the Spain (2016-2027)
  • Table 22 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Spain (2016-2027)
  • Table 23 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Spain (2016-2027)
  • Table 24 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Spain (2016-2027)
  • Table 25 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Spain (2016-2027)
  • Table 26 Incident Cases of Cutaneous Squamous Cell Carcinoma in the France (2016-2027)
  • Table 27 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the France (2016-2027)
  • Table 28 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the France (2016-2027)
  • Table 29 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the France (2016-2027)
  • Table 30 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the France (2016-2027)
  • Table 31 Incident Cases of Cutaneous Squamous Cell Carcinoma in the UK (2016-2027)
  • Table 32 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the UK (2016-2027)
  • Table 33 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the UK (2016-2027)
  • Table 34 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the UK (2016-2027)
  • Table 35 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the UK (2016-2027)
  • Table 36 Incident Cases of Cutaneous Squamous Cell Carcinoma in the Japan (2016-2027)
  • Table 37 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Japan (2016-2027)
  • Table 38 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Japan (2016-2027)
  • Table 39 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Japan (2016-2027)
  • Table 40 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Japan (2016-2027)
  • Table 41 Talimogene laherparepvec, Clinical Trials by Recruitment status, 2018
  • Table 42 Talimogene laherparepvec, Clinical Trials by Zone, 2018
  • Table 43 Pembrolizumab, Clinical Trials by Recruitment status, 2018
  • Table 44 Pembrolizumab, Clinical Trials by Zone, 2018
  • Table 45 Total 7 Major Market Size in USD, Million (2016-2027)
  • Table 46 Region wise Market Size) in USD, Million (2016-2027)
  • Table 47 7MM-Market Size by Therapy in USD, Million (2016-2027)
  • Table 48 United States Market Size in USD, Million (2016-2027)
  • Table 49 United States Market Size by Therapy in USD, Million (2016-2027)
  • Table 50 Germany Market Size in USD, Million (2016-2027)
  • Table 51 Germany Market Size by Therapy in USD, Million (2016-2027)
  • Table 52 France Market Size in USD, Million (2016-2027)
  • Table 53 France Market Size by Therapy in USD, Million (2016-2027)
  • Table 54 United Kingdom Market Size in USD, Million (2016-2027)
  • Table 55 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
  • Table 56 Spain Market Size in USD, Million (2016-2027)
  • Table 57 Spain Market Size by Therapy in USD, Million (2016-2027)
  • Table 58 Italy Market Size in USD, Million (2016-2027)
  • Table 59 Italy Market Size by Therapy in USD, Million (2016-2027)
  • Table 60 Japan Market Size in USD, Million (2016-2027)
  • Table 61 Japan Market Size by Therapy in USD, Million (2016-2027)

List of Figures

  • Figure 1 Incident Cases of Cutaneous Squamous Cell Carcinoma in 7MM (2016-2027)
  • Figure 2 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM (2016-2027)
  • Figure 3 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM (2016-2027)
  • Figure 4 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM (2016-2027)
  • Figure 5 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in 7MM (2016-2027)
  • Figure 6 Incident Cases of Cutaneous Squamous Cell Carcinoma in the US (2016-2027)
  • Figure 7 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the US (2016-2027)
  • Figure 8 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the US (2016-2027)
  • Figure 9 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the US (2016-2027)
  • Figure 10 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the US (2016-2027)
  • Figure 11 Incident Cases of Cutaneous Squamous Cell Carcinoma in the Germany (2016-2027)
  • Figure 12 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Germany (2016-2027)
  • Figure 13 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Germany (2016-2027)
  • Figure 14 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Germany (2016-2027)
  • Figure 15 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Germany (2016-2027)
  • Figure 16 Incident Cases of Cutaneous Squamous Cell Carcinoma in the Italy (2016-2027)
  • Figure 17 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Italy (2016-2027)
  • Figure 18 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Italy (2016-2027)
  • Figure 19 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Italy (2016-2027)
  • Figure 20 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Italy (2016-2027)
  • Figure 21 Incident Cases of Cutaneous Squamous Cell Carcinoma in the Spain (2016-2027)
  • Figure 22 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Spain (2016-2027)
  • Figure 23 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Spain (2016-2027)
  • Figure 24 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Spain (2016-2027)
  • Figure 25 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Spain (2016-2027)
  • Figure 26 Incident Cases of Cutaneous Squamous Cell Carcinoma in the France (2016-2027)
  • Figure 27 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the France (2016-2027)
  • Figure 28 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the France (2016-2027)
  • Figure 29 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the France (2016-2027)
  • Figure 30 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the France (2016-2027)
  • Figure 31 Incident Cases of Cutaneous Squamous Cell Carcinoma in the UK (2016-2027)
  • Figure 32 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the UK (2016-2027)
  • Figure 33 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the UK (2016-2027)
  • Figure 34 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the UK (2016-2027)
  • Figure 35 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the UK (2016-2027)
  • Figure 36 Incident Cases of Cutaneous Squamous Cell Carcinoma in the Japan (2016-2027)
  • Figure 37 Age Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Japan (2016-2027)
  • Figure 38 Gender specific incident cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Japan (2016-2027)
  • Figure 39 Stage Specific Incident Population of Cutaneous Squamous Cell Carcinoma (cSCC) in the Japan (2016-2027)
  • Figure 40 Diagnosed and treatable cases of Cutaneous Squamous Cell Carcinoma (cSCC) in the Japan (2016-2027)
  • Figure 41 Talimogene laherparepvec, Clinical Trials by Recruitment status, 2018
  • Figure 42 Talimogene laherparepvec, Clinical Trials by Zone, 2018
  • Figure 43 Pembrolizumab, Clinical Trials by Recruitment status, 2018
  • Figure 44 Pembrolizumab, Clinical Trials by Zone, 2018
  • Figure 45 Total 7 Major Market Size in USD, Million (2016-2027)
  • Figure 46 Region wise Market Size) in USD, Million (2016-2027)
  • Figure 47 7MM-Market Size by Therapy in USD, Million (2016-2027)
  • Figure 48 United States Market Size in USD, Million (2016-2027)
  • Figure 49 United States Market Size by Therapy in USD, Million (2016-2027)
  • Figure 50 Germany Market Size in USD, Million (2016-2027)
  • Figure 51 Germany Market Size by Therapy in USD, Million (2016-2027)
  • Figure 52 France Market Size in USD, Million (2016-2027)
  • Figure 53 France Market Size by Therapy in USD, Million (2016-2027)
  • Figure 54 United Kingdom Market Size in USD, Million (2016-2027)
  • Figure 55 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
  • Figure 56 Spain Market Size in USD, Million (2016-2027)
  • Figure 57 Spain Market Size by Therapy in USD, Million (2016-2027)
  • Figure 58 Italy Market Size in USD, Million (2016-2027)
  • Figure 59 Italy Market Size by Therapy in USD, Million (2016-2027)
  • Figure 60 Japan Market Size in USD, Million (2016-2027)
  • Figure 61 Japan Market Size by Therapy in USD, Million (2016-2027)
Back to Top